http://www.horizondiscovery.com/site Cancer Models for Targeted Drug Discovery Tue, 29 Jul 2008 14:54:10 +0000 http://backend.userland.com/rss092 en Research Associate, Torino, Italy Horizon Discovery is striving to provide drug discovery researchers with key missing tools that will accelerate the search for new and more effective ‘targeted’ or ‘personalised’ drugs. Central to realizing this vision is the creation and utilization of genetically-defined ‘isogenic’ cell-lines, which represent accurate laboratory based ... http://www.horizondiscovery.com/site/2008/07/07/horizon-discovery-hiring-now-for-torino-laboratory/ Horizon to Find Drug Candidates for EU Stem Cell ConsortiumHorizon to Find Drug Candidates for EU Stem Cell ConsortiumHorizon Discovery (Horizon) today announced it has signed a six figure (€) commercial discovery services contract with the Migrating Cancer Stem Cell’s Framework-6 consortium, headed by Prof. Riccardo Fodde from the Erasmus ... http://www.horizondiscovery.com/site/2008/06/16/horizon-commissioned-to-find-drug-candidates-by-eu-stem-cell-consortium/ Horizon Discovery today announces that it has appointed Dr Rob Howes, formerly Head of Assay Development and Screening at Vernalis plc, as its new R&D Director.Rob has over 10 years experience in Oncology research and development and brings to the company experience that covers target validation. new lead generation and ... http://www.horizondiscovery.com/site/2008/06/01/horizon-discovery-appoints-dr-rob-howes-as-it-rd-director/ Cell Based Assay NewsCell Based Assay NewsHorizon Discovery (Horizon) today announced it will be a founding member of VIMCAD, a consortium of leading UK Oncology research groups comprising: Cancer Research UK’s Cambridge Research Institute; Horizon Discovery in Cambridge; St George’s University of London; University of Glasgow and; the University of ... http://www.horizondiscovery.com/site/2008/05/28/horizon-discovery-to-be-a-founding-member-of-oncology-drug-discovery-consortium-funded-by-cancer-research-uk/ Horizon Discovery Limited (Horizon) announces the closing of an agreement to offer a new range of services using Horizon Discovery’s unique panel of genetically-defined human disease models called ‘isogenic’ cell lines. Hypoxium will provide a key resource in this process by enabling pharmaceutical and academic researchers to profile their targets and ... http://www.horizondiscovery.com/site/2008/05/01/horizon-discovery-sign-drug-profiling-alliance-with-hypoxium-ltd/ Horizon Discovery Limited (Horizon) announces the opening of its Gene Engineering Laboratory at the Molecular Biotechnology Center in downtown Torino, Italy. The center, funded by the Italian government, houses state-of-art laboratories, central service and full conference facilities that will house a team of molecular biologists who will expand Horizon’s unique ... http://www.horizondiscovery.com/site/2008/05/01/horizon-discovery-opens-new-gene-engineering-laboratory-in-torino/ Horizon Discovery (Horizon) has announced the formation of a partnership with Caliper Discovery Alliances and Services’ (CDAS) that expands the oncology cell line and screening capabilities of CDAS for testing single drugs and combination therapies. Through this alliance, CDAS is now able to offers, genetically-defined, and isogenic human cancer cell ... http://www.horizondiscovery.com/site/2008/04/09/horizon-discovery-sign-drug-profiling-alliance-with-caliper-life-science/ Horizon Discovery today announces the receipt of a further investment of £150,000 from Cambridge Enterprise Seed Funds and AbCam Plc, CEO Dr Jonathan Milner. The cash injection will support activity to close further significant third party deals, establish wet lab facilities and consolidate the company’s IP portfolio. Cambridge Enterprise Seed ... http://www.horizondiscovery.com/site/2008/04/07/horizon-discovery-secures-further-investment/ Horizon Discovery (Horizon) has signed a commercial agreement to supply leading global Pharma company AstraZeneca with its isogenic cell-lines. The financial terms of the deal remains confidential but involve payment of up-front and milestone payments. Chris Torrance, Horizon CEO says: “We are delighted to have AstraZeneca as an early-adopter of our ... http://www.horizondiscovery.com/site/2008/01/05/horizon-discovery-ltd-signs-a-commercial-agreement-with-astrazeneca-uk-ltd/ Horizon Discovery (Horizon) has signed a second commercial agreement to supply leading US biotechnology company Genentech, Inc. with access to its OncoGene panel of isogenic cell-lines. The financial terms of both deals remain confidential but involve payment of up-front, annual renewal and milestone payments. Chris Torrance, Horizon CEO says: "We are ... http://www.horizondiscovery.com/site/2007/12/01/horizon-discovery-signs-a-commercial-agreement-with-genentech-inc/